Lincoln Pharmaceuticals Limited

NSEI:LINCOLN Stock Report

Market Cap: ₹12.3b

Lincoln Pharmaceuticals Valuation

Is LINCOLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LINCOLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LINCOLN (₹616.85) is trading above our estimate of fair value (₹114.53)

Significantly Below Fair Value: LINCOLN is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LINCOLN?

Key metric: As LINCOLN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LINCOLN. This is calculated by dividing LINCOLN's market cap by their current earnings.
What is LINCOLN's PE Ratio?
PE Ratio12.7x
Earnings₹966.39m
Market Cap₹12.31b

Price to Earnings Ratio vs Peers

How does LINCOLN's PE Ratio compare to its peers?

The above table shows the PE ratio for LINCOLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21x
524280 Kopran
20.6xn/a₹10.9b
506197 Bliss GVS Pharma
19.6xn/a₹12.4b
524774 NGL Fine-Chem
27.3xn/a₹11.3b
506260 Anuh Pharma
16.4xn/a₹9.7b
LINCOLN Lincoln Pharmaceuticals
12.7xn/a₹12.3b

Price-To-Earnings vs Peers: LINCOLN is good value based on its Price-To-Earnings Ratio (12.7x) compared to the peer average (21x).

Price to Earnings Ratio vs Industry

How does LINCOLN's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$74.22m
524652 Ind-Swift
2.8xn/aUS$13.24m
No more companies available in this PE range
LINCOLN 12.7xIndustry Avg. 35.6xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: LINCOLN is good value based on its Price-To-Earnings Ratio (12.7x) compared to the Indian Pharmaceuticals industry average (35.6x).

Price to Earnings Ratio vs Fair Ratio

What is LINCOLN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LINCOLN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LINCOLN's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IOL Chemicals and Pharmaceuticals

₹21.8b

Manufactures and sells pharmaceutical and chemical products in India and internationally.

IOLCP

₹371.55

7D

-6.7%

1Y

-12.4%

Solara Active Pharma Sciences

₹36.4b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

SOLARAPP

₹468.50

7D

-5.7%

1Y

n/a

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹944.45

7D

-3.5%

1Y

18.1%